Clinical Trial Update: Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating the combination of cabozantinib and lanreotide for gastroenteropancreatic neuroendocrine tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumor

Drugs mentioned

• Cabometyx (cabozantinib)
• Somatuline (lanreotide)

Snippet

Sponsor: National Health Research Institutes, Taiwan | Conditions: Neuroendocrine Tumors,Gastroenteropancreatic | Phase 1, Phase 2 | Status: RECRUITING